Bristol Myers Squibb (NYSE:BMY) and Bain Capital have announced the establishment of a new independent biopharmaceutical ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

We recently compiled a list of 11 Best Undervalued Stocks to Invest in Now. Lincoln National Corporation stands third on our ...

HS Hyosung Advanced Materials has selected Bain Capital as the preferred bidder for its tire steel cord business unit. According to the investment banking (IB) industry on the 28th, HS Hyosung ...

Bain Capital is on the cusp of signing a deal to buy UK broker Jensten from private equity (PE) firm Livingbridge, Insurance ...

Bain Capital's Bridge Data Centres (Bridge DC) has broken ground on a facility in Thailand. Located south of Bangkok in the ...

Legendary 'is definitely in the ears of the beholder. We look for artists that have a true fan base,' Bain Capital's Angelo ...

Back in May, Bain and Botanic spent $26 million to acquire the property from Fujifilm Recording Media. The 15-acre site will ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing immunology drugs, backed by Bain's $300 million financing round, ...

Princeton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, ...

Bain Capital and Bristol Myers Squibb have formed a new biopharmaceutical company focused on developing new therapies for autoimmune diseases. The newly formed company launches with a $300 million ...